BACKGROUND: Cryptococcosis is a potential fatal disease, especially in immunocompromised patients. In China, the profile of cryptococcosis is unclear. Therefore, we summarize the epidemiology and therapy of cryptococcosis in china. METHODS: All cases reports about cryptococcosis in China were collected from CBMdisk database (China Biology and Medicine data disc) with key words of cryptococcosis, or cryptococcal infection, or cryptococcus, and case. The features of the cryptococcosis were retrospectively analyzed. RESULTS: There were 1,032 reports about cryptococcosis, including 8,769 cases. Among them, there were 16% patient with AIDS/HIV, and 17% ones without underlying diseases. There were 2,371 cases of CNS infection. Among them of 2,068 cases, the treatment protocols and outcome were clearly described. The percentages of patients who received intrathecal treatment of amphotericin B(AmB), AmB + 5-FC(5-fluorocytosine), AmB + FCZ(fluconazole), and AmB + 5-FU + FCZ in each medication group were 10, 43, 53, and 33%, respectively. The mortalities were significantly lower in the AmB, Amb + 5-FC, AmB + FCZ intrathecal treatment groups compared with their non-intrathecal treatment controls (6% vs. 23%, 25% vs. 35%, 20% vs. 30%, respectively, P < 0.05), but not in the intrathecal AmB + 5-FU + FCZ group (35% vs. 26%, P > 0.05). CONCLUSION: The Chinese cryptococcosis had its own special clinical features, such as more patients without identifiable underlying diseases. Intrathecal injection of amphotericin B was effective treatment method for cryptococcal CNS infection in China.
BACKGROUND:Cryptococcosis is a potential fatal disease, especially in immunocompromised patients. In China, the profile of cryptococcosis is unclear. Therefore, we summarize the epidemiology and therapy of cryptococcosis in china. METHODS: All cases reports about cryptococcosis in China were collected from CBMdisk database (China Biology and Medicine data disc) with key words of cryptococcosis, or cryptococcal infection, or cryptococcus, and case. The features of the cryptococcosis were retrospectively analyzed. RESULTS: There were 1,032 reports about cryptococcosis, including 8,769 cases. Among them, there were 16% patient with AIDS/HIV, and 17% ones without underlying diseases. There were 2,371 cases of CNS infection. Among them of 2,068 cases, the treatment protocols and outcome were clearly described. The percentages of patients who received intrathecal treatment of amphotericin B(AmB), AmB + 5-FC(5-fluorocytosine), AmB + FCZ(fluconazole), and AmB + 5-FU + FCZ in each medication group were 10, 43, 53, and 33%, respectively. The mortalities were significantly lower in the AmB, Amb + 5-FC, AmB + FCZ intrathecal treatment groups compared with their non-intrathecal treatment controls (6% vs. 23%, 25% vs. 35%, 20% vs. 30%, respectively, P < 0.05), but not in the intrathecal AmB + 5-FU + FCZ group (35% vs. 26%, P > 0.05). CONCLUSION: The Chinese cryptococcosis had its own special clinical features, such as more patients without identifiable underlying diseases. Intrathecal injection of amphotericin B was effective treatment method for cryptococcal CNS infection in China.
Authors: J E Bennett; W E Dismukes; R J Duma; G Medoff; M A Sande; H Gallis; J Leonard; B T Fields; M Bradshaw; H Haywood; Z A McGee; T R Cate; C G Cobbs; J F Warner; D W Alling Journal: N Engl J Med Date: 1979-07-19 Impact factor: 91.245
Authors: S X Wu; N R Guo; X F Li; W Q Liao; M Chen; Q Q Zhang; C Y Li; R Y Li; G S Bulmer; D M Li; L Y Xi; S Lu; B Liu; Y C Zheng; Y P Ran; Y Z Kuan Journal: Mycopathologia Date: 2011-04-21 Impact factor: 2.574
Authors: John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Vishnu Chaturvedi; Jean-Philippe Bouchara; Ferry Hagen; Ana Alastruey-Izquierdo; Hamid Badali; Anamelia Lorenzetti Bocca; Jose F Cano-Lira; Cunwei Cao; Sudha Chaturvedi; Sanjay H Chotirmall; Anne D van Diepeningen; Jean-Pierre Gangneux; Jesus Guinea; Sybren de Hoog; Macit Ilkit; Rui Kano; Weida Liu; Nilce M Martinez-Rossi; Marcia de Souza Carvalho Melhem; Mario Augusto Ono; Yuping Ran; Stephane Ranque; Celia Maria de Almeida Soares; Takashi Sugita; Philip A Thomas; Anna Vecchiarelli; Nancy L Wengenack; Patrick C Y Woo; Jianping Xu; Rosely M Zancope-Oliveira Journal: Mycopathologia Date: 2018-11-30 Impact factor: 2.574
Authors: H Zheng; Q Chen; Z Xie; D Wang; M Li; X Zhang; Y Man; J Lao; N Chen; L Zhou Journal: Eur J Clin Microbiol Infect Dis Date: 2016-01-20 Impact factor: 3.267
Authors: Min Chen; Yuan Xu; Nan Hong; Yali Yang; Wenzhi Lei; Lin Du; Jingjun Zhao; Xia Lei; Lin Xiong; Langqi Cai; Hui Xu; Weihua Pan; Wanqing Liao Journal: Front Med Date: 2018-01-11 Impact factor: 4.592